Literature DB >> 2081136

Individual differences mean that the costs of treatment of hypertension cannot readily be quantified.

N M Kaplan.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2081136     DOI: 10.1007/BF02026488

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


× No keyword cloud information.
  5 in total

Review 1.  The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: a review of randomized controlled trials.

Authors:  S W MacMahon; J A Cutler; C D Furberg; G H Payne
Journal:  Prog Cardiovasc Dis       Date:  1986 Nov-Dec       Impact factor: 8.194

2.  Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study.

Authors:  J Wikstrand; I Warnold; G Olsson; J Tuomilehto; D Elmfeldt; G Berglund
Journal:  JAMA       Date:  1988-04-01       Impact factor: 56.272

3.  Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). The IPPPSH Collaborative Group.

Authors: 
Journal:  J Hypertens       Date:  1985-08       Impact factor: 4.844

4.  MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1985-07-13

5.  Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial.

Authors:  L Wilhelmsen; G Berglund; D Elmfeldt; T Fitzsimons; H Holzgreve; J Hosie; P E Hörnkvist; K Pennert; J Tuomilehto; H Wedel
Journal:  J Hypertens       Date:  1987-10       Impact factor: 4.844

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.